Please assess the completion status of the following clinical trial:

Trial Title: A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female. (Age limit 18-70)~* HCV PCR confirmed active infection, genotype 1 or 3.~* If female, must have negative urine test results for pregnancy during initial screening period (for trial inclusion) and be advised of limited safety data in pregnancy.~* Current illicit drug use established through participant history.~* Able to provide informed consent, agreeing to trial and clinical monitoring criteria~Exclusion Criteria:~* Aggressive or violent behaviour.~* Platelet count \< 75000000000 /ml~* Alanine transaminase \> 350 Units/l~* Inability to provide informed consent.~* Clinical history or abnormal valves for albumin\< 30 g/l, Bilirubin \>35 umol/l or prothrombin time \>1.5 consistent with decompensated liver failure Childs-Pugh B or C~* Clinical history of primary hepatocellular carcinoma~* Pregnancy or breast feeding.~* Participation in a drug trial within the previous 30 days~* Hepatitis B surface antigen positive~* HIV infection.~* Hypersensitivity to elbasvir and grazoprevir~* Hypersensitivity to sofosbuvir (genotype 3 infected-participants ony)~* Currently being treated with an inhibitor of organic anion transporting polypeptide 1B, e.g. rifampicin, atazanavir, daruavir, lopinavir, saquinavir, tipranavir, cobicistat or ciclosporin.~* Currently being treated with inducers of cytochrome P450 3A or P-glycoprotein, such as efavirenz, phenytoin, carbamazepine, bosentan, etravirine, modafinil or St John's Wort (Hypericum perforatum)~* Currently being treated with amiodarone (Participants infected with genotype 3 HCV only)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Daily observed therapy (Type: EXPERIMENTAL): Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a daily, observed basis by either the nurse or a community pharmacist.
- Fortnightly pick-up (Type: ACTIVE_COMPARATOR): Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse.
- Fortnightly pick-up +psych intervention (Type: ACTIVE_COMPARATOR): Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse. In addition, this group will receive a one-off interview with the researcher to complete a psychological intervention designed to improve adherence to the medication regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).